Escudier, B
Michaelson, M D
Motzer, R J
Hutson, T E
Clark, J I
Lim, H Y
Porfiri, E
Zalewski, P
Kannourakis, G
Staehler, M
Tarazi, J
Rosbrook, B
Cisar, L
Hariharan, S
Kim, S
Rini, B I
Article History
Received: 10 February 2014
Revised: 7 April 2014
Accepted: 10 April 2014
First Online: 13 May 2014
Competing interests
: BE has served as an advisor for Bayer, Pfizer, and Novartis and has received honoraria from Bayer, Roche, Pfizer, Genentech, Novartis, and AVEO. MDM has served as an advisor for Pfizer, Novartis, AVEO, Genentech, and Abbott and has received research funding from GlaxoSmithKline, Genentech, Pfizer, Novartis, Eisai, Bayer, and Abbott. RJM has served as an advisor for Pfizer, Genentech, and AVEO, received research funding from Pfizer, Novartis, and GlaxoSmithKline, and provided paid expert testimony for Pfizer. TEH has served as an advisor for and received honoraria and research funding from Pfizer, Bayer, GlaxoSmithKline, Genentech, AVEO, and Novartis. JIC has served on speakers’ bureaus for Pfizer, Prometheus, and Bristol-Myers Squibb and on advisory boards for Bayer. EP has served as an advisor for Pfizer, Astellas, Bayer, and Novartis and received research funding from Pfizer and GlaxoSmithKline. PZ has served as an advisor for Pfizer and Novartis. GK has served as an advisor for Pfizer. MS has served as an advisor for and received honoraria and research funding from Pfizer, Bayer, Roche, Novartis, and GlaxoSmithKline. JT, BR, LC, and SH are employees of Pfizer Inc and own Pfizer stock. SK, employed at Pfizer at the time of the study described here, is currently employed by Mirna Therapeutics and owns stock in Pfizer and Mirna Therapeutics. BIR has served as an advisor for and received research funding from Pfizer. HYL declares no conflict of interest.